REDWOOD CITY, Calif., March 11, 2021 (GLOBE NEWSWIRE) — via InvestorWire- Avinger, Inc. (Nasdaq: AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that Mark Weinswig, CFO, will be attending the Q1 Virtual Investor Summit. Management will conduct an overview presentation available on the investor relations section of Avinger’s website, www.avinger.com, and be available for one-on-one investor meetings throughout the day.
| Event | Q1 Investor Summit |
| Date | March 23-25th, 2021 |
| Presentation | March 23rd @ 4:40PM ET |
| Location | https://zoom.us/webinar/register/WN_1WnGv7hXQmCjpg7cirqJ_w |
About The Investor Summit
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors.
To request complimentary investor registration: please visit our website at www.investorsummitgroup.com
Contact:
Brittney Blocker at brittney@investorsummitgroup.com
Matt Kreps, Managing Director, Darrow Associates Investor Relations, mkreps@darrowir.com, (214) 597-8200
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot and Tigereye™ family of chronic total occlusion (CTO) crossing catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.
Follow Avinger on Twitter and Facebook.
Wire Service Contact:
InvestorWire (IW)
Los Angeles, California
212.418.1217 Office
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN…
BOUCHERVILLE, Québec, June 28, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL, LSL.DB)…
SALINAS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL;…
MINNEAPOLIS, MN, US, June 28, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC: PETV, PETVW),…
BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or…
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a…